Research and Development

Here’s a quick look at some of the biggest movers of the week:Sophiris Bio (Nasdaq: SPHS) stock rose to nearly …

The NHS will offer devices and apps for free to help patients manage their health, starting in UK next year.

GlaxoSmithKline (LSE: GSK), along with Innoviva (NASDAQ: INVA), have presented positive top-line results from a pivotal Phase III trial for …

Hutchison China MediTech (Nasdaq: HCM) on Monday said it is expanding Phase II trials in non-small cell lung cancer to …

A US Federal safety board is set to review a proposal for the first human use of the gene editing …

The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …

Pfizer (NYSE: PFE) has broken ground on a new $200 million biologics clinical manufacturing facility in Andover, Massachusetts. This expansion …

Adding to the growing list of healthcare applications, a new technology claims to have created the first anti-stress biofeedback bracelet …

The National Institute for Health and Care Excellence (NICE) has announced that that it has not recommended Roche’s melanoma drug, …

The Scottish Medicines Consortium has recommended Adenuric (febuxostat), a treatment for a severe complication that can affect chemotherapy patients in …

US-based biopharmaceutical company, Chiasma (NASDAQ: CHMA), has announced substantial job cuts as it attempts to restructure following the US Food …

The UK biotechnology sector is going from strength to strength, having raised an “unprecedented” £900 million on the London Stock …

Roche (SIX: RO) has announced that the European Commission has approved Gazyvaro (obinutuzumab), in combination with bendamustine chemotherapy, in patients …

Israeli drugmaker Teva (NYSE: TEVA) has returned full rights to a drug for heart condition in late stage trials to …

Marathon Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …